Maria L. Padilla, MD, and Timothy P. M. Whelan, MD
discuss efficacy, safety, and current evidence on combining nintedanib and pirfenidone


CME/CE Information

Activity Title Combining Nintedanib and Pirfenidone
Topic IPF
Accreditation Type AMA PRA Category 1 Credits™
Release Date June 30, 2016
Expiration Date June 29, 2017
Estimated Time to Complete Activity 15 minutes


Upon completion of the activity, participants should be able to:

  • Examine emerging research related to IPF treatment
  • Demonstrate shared-decision making in IPF management


Maria L. Padilla, MD
Professor, Medicine, Pulmonary, Critical Care and Sleep Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Timothy P. M. Whelan, MD
Associate Professor
Division of Pulmonary and Critical Care
Medical University of South Carolina
Charleston, South Carolina


  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ACPE pharmacy credit—your CE credits will be submitted electronically to the CPE Monitor.



This activity is provided by The France Foundation.


This activity is intended for pulmonologists, surgeons, critical care clinicians, advanced practice nurses, and other health care professionals involved in the management of patients with IPF.


Healthcare providers managing patients with IPF need to be up to date on recent analyses of clinical studies and new research. Providers can individualize treatment by incorporating these findings with patient preferences and lifestyle in the shared decision making process. PILOT Connect offers the latest evidence with expert perspective so that providers can get answers to their questions about emerging research and the clinical use of IPF therapies.


The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty report that they have relevant financial relationships to disclose:

  • Maria Padilla, MD, has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech. She has also received honoraria from Genentech.
  • Timothy P. M. Whelan, MD, has received grants/research support Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, InterMune/Genentech, Pulmonary Fibrosis Foundation, and Roche. He has also served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., InterMune/Genentech, and LifePoint of South Carolina.


TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation assumes no liability for the information herein.


Copyright © 2016 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.


The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at


If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..


Access other Therapeutic Areas: